(AmericanProsperity.com) – The Food and Drug Administration has just approved Moderna’s second-ever product, their RSV vaccine for seniors. This vaccine is aimed at adult seniors over the age of sixty who are suffering from Respiratory Syncytial Virus.
The company has been looking to develop more vaccines as they have had less demand for their COVID-19 vaccine, which is the only other product that Moderna has. This approval of the RSV vaccine is based on late-stage trials with older adults who are more vulnerable to RSV. RSV kills between six thousand and ten thousand seniors every single year according to the Center for Disease Control and Prevention.
In June, an advisory panel is set to vote on recommendations regarding the vaccine and the intended target population for the shot. The company says that the recommendation will be the same or similar as existing RSV shots from GSK and Pfizer. A full approval would mean that Moderna’s shot would be able to compete alongside the two existing vaccines.
Moderna CEO Stéphane Bancel spoke out saying, “The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform. With mRESVIA, we continue to deliver for patients by addressing global public health threats related to infectious diseases.”
The company is working on more than forty different products and many are in late-stage trials and could begin getting approval as soon as next year. They are said to be developing a COVID-Flu combination shot, a stand-alone flu shot, a personalized cancer vaccine, and multiple vaccines against different viruses.
Copyright 2024, AmericanProsperity.com
